Key result
Combination drug therapy is often necessary to achieve treatment goals for diabetic dyslipidaemia, emphasizing the importance of both lowering LDL-C and raising HDL-C in high-risk individuals.
Case Report (n=1)
This case study highlights the necessity of combination lipid-lowering therapy to address the triad of diabetic dyslipidaemia and reduce cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Highlights potential role of combination therapy in diabetic dyslipidaemia; hypothesis-generating and should not yet change practice.
Diabetic dyslipidaemia refers to the triad of elevated levels of triglycerides and small, dense LDL-C particles and low levels of HDL-C. These lipid abnormalities are largely responsible for the increased risk of cardiovascular complications in patients with diabetes. This case study outlines a rational approach to the treatment of each of these lipid abnormalities and emphasises the importance of both lowering the LDL-C and raising the HDL-C in high-risk individuals. Combination drug therapy will often be necessary to achieve treatment goals in these patients.
No takes yet. Share an insight, caveat, or question.
Charles A. Reasner (2007) conducted a case report in Diabetic dyslipidaemia (n=1). Combination drug therapy was evaluated. Combination drug therapy is often necessary to achieve treatment goals for diabetic dyslipidaemia, emphasizing the importance of both lowering LDL-C and raising HDL-C in high-risk individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: